ADC Therapeutics reports Q1 EPS (13c) vs. (22c) last year

Reports Q1 revenue $20.0M, consensus $19.99M. As of March 31, cash and cash equivalents were $231.0M vs. $261.3M as of December 31, 2025. The company has an expected cash runway at least into 2028. “During Q1, we continued to build momentum across our ZYNLONTA program,” said CEO . “Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in Q2, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA’s role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027.”